Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
about
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey modelImaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's diseaseReduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain.L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.Neurochemical and electrophysiological characteristics of rat striatal neurons in primary culture.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Modeling Parkinson's disease in primates: The MPTP modelThe selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.Pain and motor complications in Parkinson's disease.Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.Understanding graft-induced dyskinesia.Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.Striatal histone modifications in models of levodopa-induced dyskinesia.Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum.Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
P2860
Q24646533-E939D8B1-AF3C-43BA-B5B8-ACD508C8C8E4Q27317506-BF2BA2A6-8966-4B16-B581-9161E0ADD264Q33285540-CFD913F8-7FC7-4890-B75B-2EE00E68E163Q33954124-FB3AE156-DDF8-42FE-A65C-E83D864E4AB5Q34071218-123FF890-E533-4756-B388-61A4F07689C0Q34094008-6CC0D4AF-2436-4365-A793-A84066B987BBQ34165820-6141762D-DC1A-4DC9-9E4F-009ACB011243Q34673205-7A6D52B3-2710-4E7E-B426-9534D2A14D61Q35196411-86AF123F-15BB-4CEC-8F89-01B9B4F34D4DQ35208420-65BF2D34-9E48-419A-A382-963194CBECE0Q35589979-223ACC9E-6B37-4927-BD33-D804BC411296Q35765748-FDA21D3B-D254-4F7B-9928-B53F9E722A03Q36026631-39D1387F-DA66-4B83-9C82-B0992DCA42A8Q36226497-20B458AC-BB13-4E17-A611-E02A67E50AC1Q36241219-52EBD9D6-79AD-49EA-9B67-3DE666BED958Q36727014-BFE9F2F6-BA68-4B1B-8380-B77265481ABEQ37792121-4688B4FB-8270-44C7-8190-8B739B65B60CQ38091388-6964BE6C-020D-45B1-80A0-6923CD9B7715Q42486325-5EFD99E9-1BE2-445B-8E33-F6DFFBBC0034Q42573127-14561BD4-F75C-45E6-A6D2-FC004CDEA201Q42747563-7E136006-44B9-4158-8FC7-BA9B493C1D3CQ43067885-FF1A110E-492C-4BD0-B2E5-54BA23645631Q44228322-B7C01E7F-582B-4DE1-9364-1515B9A93050Q44350349-1E287022-995F-4DEB-A3BA-38FDA573138FQ46987576-4E1828D8-EC68-48B3-9618-47514D9B14A0Q47137434-5C23485D-535D-4FC1-82E6-4865FB45854CQ48243272-1808C4D7-C3F9-4EFC-9A41-59A55AA6D314
P2860
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@en
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@nl
type
label
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@en
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@nl
prefLabel
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@en
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@nl
P2093
P921
P1476
Increased striatal pre-proenke ...... inesia in Parkinson's disease.
@en
P2093
Alan R Crossman
Brian Henry
Susan Duty
P304
P356
10.1016/S0014-4886(03)00064-5
P407
P577
2003-10-01T00:00:00Z